Aurora Cannabis rebuts Curaleaf statements on hostile bid, says claims inaccurate
ACB•Aurora responds to Curaleaf takeover materials
Aurora Cannabis corrected what it called inaccurate statements in Curaleaf’s unsolicited takeover bid materials.
Shareholders were told to take no action while the board and a special committee review the offer.
Aurora disputes Curaleaf’s claims on German exposure and cultivation
Aurora said international net revenue rose 17% year over year in fiscal Q1 2027, with Germany a key driver.
It disputed Curaleaf’s claims on German reimbursement exposure, citing less than 10% of German volume before regulatory changes.
Aurora rejected Curaleaf’s criticism of cultivation performance, calling it outdated and pointing to expanded EU-GMP capacity over five years.
